Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Among authors: hagopian w. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial.
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Herold KC, et al. Among authors: hagopian w. N Engl J Med. 2002 May 30;346(22):1692-8. doi: 10.1056/NEJMoa012864. N Engl J Med. 2002. PMID: 12037148 Free article. Clinical Trial.
Treatment of type 1 diabetes with anti-CD3 monoclonal antibody.
Glandt M, Hagopian W, Herold KC. Glandt M, et al. Among authors: hagopian w. Rev Endocr Metab Disord. 2003 Dec;4(4):361-8. doi: 10.1023/a:1027354129493. Rev Endocr Metab Disord. 2003. PMID: 14618021 Review. No abstract available.
Insulin secretion in type 1 diabetes.
Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Steele C, et al. Diabetes. 2004 Feb;53(2):426-33. doi: 10.2337/diabetes.53.2.426. Diabetes. 2004. PMID: 14747294 Clinical Trial.
A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. Herold KC, et al. Among authors: hagopian w. Diabetes. 2005 Jun;54(6):1763-9. doi: 10.2337/diabetes.54.6.1763. Diabetes. 2005. PMID: 15919798 Free PMC article. Clinical Trial.
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group. Herold KC, et al. Among authors: hagopian w. Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14. Clin Immunol. 2009. PMID: 19443276 Free PMC article. Clinical Trial.
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Herold KC, et al. Among authors: hagopian w. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8. Diabetes. 2013. PMID: 23835333 Free PMC article. Clinical Trial.
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network. Perdigoto AL, et al. Among authors: hagopian w. Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19. Diabetologia. 2019. PMID: 30569273 Free PMC article.
220 results